The Journal of infectious diseases · 2025
Human Papillomavirus Prevalence Among Australian Men Aged 18-35 Years in 2015-2018 According to Vaccination Status and Sexual Orientation.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Balgovind Prisha, Aung Eithandee, Shilling Hannah, Murray Gerald L, Molano Monica, Garland Suzanne M, Fairley Christopher K, Chen Marcus Y, Hocking Jane S, Ooi Catriona, McNulty Anna, McCloskey Jenny, McNamee Kathleen, Bateson Deborah, Owen Louise, Tabrizi Sepehr N, Machalek Dorothy A
Аннотация
BACKGROUND: Australia introduced a national human papillomavirus (HPV) vaccination program for girls in 2007 and boys in 2013, achieving high coverage. We assessed HPV prevalence among men who have sex with women (MSW) and men who have sex with men (MSM) aged 18-35 years and examined program effects.
METHODS: Between 2015-2018, men self-collected a penile or intra-anal swab for HPV genotyping. Vaccination status was confirmed with the National Register. HPV prevalence was examined by age groups and vaccination status.
RESULTS: Prevalence of quadrivalent vaccine-targeted HPV types (6, 11, 16, 18) was 10.6% (95% confidence interval [CI], 8.7%-12.8%) in unvaccinated MSW and 10.7% (95% CI, 5.7%-19.3%) in vaccinated MSW (P = .96). Prevalence was 40.3% (95% CI, 36.0%-44.8%) in unvaccinated MSM and 29.9% (95% CI, 23.1%-37.8%) in vaccinated MSM (P = .02). Among those with confirmed doses, quadrivalent types were detected in 0% (95% CI, 0%-7.7%; n = 46) of men who had their first dose at 13-19 years and 37.2% (95% CI, 27.5%-47.8%; n = 94) in those who received their first dose at 20 years or older.
CONCLUSIONS: Our data demonstrate the importance of universal adolescent HPV vaccination to ensure MSM receive the same benefits as MSW.
METHODS: Between 2015-2018, men self-collected a penile or intra-anal swab for HPV genotyping. Vaccination status was confirmed with the National Register. HPV prevalence was examined by age groups and vaccination status.
RESULTS: Prevalence of quadrivalent vaccine-targeted HPV types (6, 11, 16, 18) was 10.6% (95% confidence interval [CI], 8.7%-12.8%) in unvaccinated MSW and 10.7% (95% CI, 5.7%-19.3%) in vaccinated MSW (P = .96). Prevalence was 40.3% (95% CI, 36.0%-44.8%) in unvaccinated MSM and 29.9% (95% CI, 23.1%-37.8%) in vaccinated MSM (P = .02). Among those with confirmed doses, quadrivalent types were detected in 0% (95% CI, 0%-7.7%; n = 46) of men who had their first dose at 13-19 years and 37.2% (95% CI, 27.5%-47.8%; n = 94) in those who received their first dose at 20 years or older.
CONCLUSIONS: Our data demonstrate the importance of universal adolescent HPV vaccination to ensure MSM receive the same benefits as MSW.